Floatz logo

Tarlatamab

Neuroendocrine Carcinoma of Prostate

Inkeun Parkmonoclonal_antibodyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

32 Active assets in the Neuroendocrine Carcinoma of Prostate cohort.

Asset / SponsorPhaseRating
Carboplatin
Phanes Therapeutics
Phase 2BB
Oxodotreotide
Novartis Pharmaceuticals
Phase 2B
Alisertib
Weill Medical College of Cornell University
Phase 2B
Cediranib
National Cancer Institute (NCI)
Phase 2CCC
Sacituzumab Tirumotecan
Virginia Commonwealth University
Phase 2CCC

View all 35 →

Same molecule, other indications

Tarlatamab is also rated in:

small cell lung carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
medullary thyroid gland carcinomaDormant
B
Indicative ·
60 / 100
View asset →
neuroendocrine carcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →